Product Description
Mechanisms of Action: D2 Antagonist,5-HT2A Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Livzon Group Livzon Pharmaceutical Factory
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2200063354 | N/A |
Not yet recruiting |
Depressive Disorder, Major |
2023-12-31 |
|
| ChiCTR2200063355 | N/A |
Recruiting |
Schizophrenia |
2023-12-31 |
|
| CTR20222399 | N/A |
Completed |
Schizophrenia |
2023-03-03 |
|
| CTR20212498 | N/A |
Completed |
Schizophrenia |
2021-11-24 |